Index

Acts, urges and, 3
Acute obsessive-compulsive disorders, 137
Affective disorders, 170
Age level
  onset and, 5
  prognosis and, 112
  psychosurgery and, 35
Agoraphobia, 83, 86–87, 117. See also Phobias
Ambivalence, 149
Amitriptyline, 182, 183
Amphetamine psychosis, 175, 176
Anal-erotic character, 219–220
Animal studies, 11
  flooding, 39
  pharmacology, 175–176
Anterior cingulectomy, 199
Antidepressants, 31, 181–183,
  233–235, 239
  behavior therapy and, 189–192
  clomipramine, 183–188
  See also Pharmacotherapy
Anxiety
  behavioral treatment, 60
  blocking procedures, 66
  cognitive-behavior theory, 55
Anxiety (cont.)
  diagnosis, 168, 169, 222–223
  exposure and response prevention, 84, 88, 90, 93, 96, 98,
    99, 100
  exposure procedures and, 62,
    101–111
  fear/avoidance model, 51, 52,
    53, 54
  functional diversity and,
    216–217
  habituation and, 110
  obsessional-compulsive disorders, 50–51, 226–232
  persistence, 15
  pharmacology, 180–181, 195
  phobias, 52
  predictor variables, 241–242
  prognosis and, 114–115
  psychodynamic explanations, 133, 134
  psychotherapy, 137, 138
  Anxiety/discomfort theory, 15–19
  Anxiolytics, 179
  Apotrepic therapy, 73–74, 91. See also Exposure and response prevention therapy
Arousal, 241–242  
Assertiveness training, 69  
Assessment  
pharmacotherapy and, 170–175  
psychosurgery and, 196  
treatment and, 243–244  
See also Diagnosis; Prognosis  
Athetosis, 175  
Attribution therapy, 69  
Aversion-relief paradigm  
blocking procedures, 66–67  
exposure procedures, 65  
prognosis, 72  
Aversion therapy  
blocking procedures, 66–67, 68  
prognosis, 72  
thought stopping and, 69  
Avoidance behavior  
behavior therapy, 39  
fear and, 15  
fear/avoidance model, 52  
obsessions and, 25, 26  
Behavior, compulsions and, 58  
Behavior therapy, 49–119  
assessment and, 243  
blocking procedures, 66–70  
effectiveness of, 229  
exposure and response prevention therapy, 73–115  
exposure procedures, 61–66  
future research and, 235–238  
obsessive-compulsive disorders and, 49–51, 155, 157  
obsessive-compulsive disorders classification and, 56–60  
obsessive-compulsive disorders models and, 51–56  
pharmacotherapy with, 239–240  
psychotherapy contrasted, 157–160, 163–164  
treatment, 37–41, 60–73  
Benzodiazepine derivates, 181  
Beta adrenergic blocking agents, 195  
Bimedial leucotomy, 199–200  
Biochemistry, 175–178  
Biofeedback, 71  
Blocking procedures, 66–70  
behavioral treatment and, 60  
cognitive compulsions, 100, 116  
exposure procedures compared, 64–65, 70–71  
prognosis, 72–73  
Borderline syndromes, 168  
Brain, 197. See also Psychosurgery  
Celibacy rates, 6  
Checking compulsions  
anxiety and, 16, 17, 19  
classification, 56  
cleaning compulsions and, 13–14  
exposure and response prevention therapy, 76  
onset mode and, 11  
response prevention and, 41  
Chlordiazepoxide, 180, 181  
Chlorpromazine, 63, 178, 179  
Chorea, 175  
Chronic obsessive-compulsive disorders, 137  
Classical conditioning, 51  
Cleaning compulsions  
anxiety and, 16, 17, 19  
checking compulsions and, 13–14  
classification, 56  
onset mode and, 11  
phobias and, 10  
sex differences and, 6  
Clomipramine, 31–32, 74, 110, 113, 183–188, 194, 233, 237, 239  
behavior therapy and, 189–190, 191–192
Clomipramine (cont.)
combination treatments, 188
placebo-controlled double-blind
studies, 186-187
standard controlled studies,
187-188
uncontrolled studies, 184-186
Cognition
behavior therapy and, 158
blocking procedures, 67-68
compulsions and, 58
exposure treatment and,
118-119
genesis of OCD and, 11
habitation and, 108
obsessive-compulsive disorders
and, 49, 50
See also Intrusive thoughts
Cognitive behavior theory, 54-56,
155
Cognitive compulsions, 99-100,
115-116
Compulsions
anxiety and, 53
apotrepic therapy, 73
aversive properties of, 54
behavioral treatment, 60-61
classification of, 56, 58-60
conditions in, 4
defined, 2-3, 8, 50-51
exposure procedures and, 62,
65-66
fear/avoidance model, 51
obsessions and, 3
See also Obsessions; Obsessive-
compulsive disorders
Compulsive urges, 19-24
acts and, 3
defined, 19-20
features of, 23-24
spontaneous decay of, 21-23,
24
Covert sensitization, 67, 70
Crisis, 141-142
Cyclothymic disease, 170
Daydreaming, 172
Delusions, 8
Demography, 6
Depression
diagnosis and, 168, 169-170 ex-
posure and response preven-
tion therapy, 93, 97
obsessive-compulsive disorders
and, 6, 8-10, 232-235
pharmacology and, 31, 181-183,
189-190
prognosis and, 113-114, 115,
117-118, 240-241
Desensitization, 61
exposure and response preven-
tion, 87
obsessionals and, 63
prognosis, 72
treatment, 38
See also Imaginal desensitiza-
tion; Systemic desensitization
Desipramine, 183
Diagnosis
functional formulations,
222-226
pharmacotherapy and, 168-170
psychosurgery and, 196
treatment and, 137, 236
unifying clinical concepts in,
218-221
See also Assessment; Prognosis
Diagnostic and Statistical Manual
of Mental Disorders (DSM-
III), 168, 227, 236
Diazepam, 180-181, 188
Discomfort, 20-21. See also
Anxiety
Displacement, 135, 138, 146
Distraction, 110
Dopaminergic drugs, 175-176
Dothiepin, 183
Dysphoria, 28–29

Ego strength. See Self-esteem

Electroconvulsive therapy, 183
aversion procedures, 65, 66–67
blocking procedures, 67, 68
ethics and, 72

Epilepsy, 171, 196
Episodic course, 170–171
Escape response, 51, 52
Ethics, 72

Etiology, 57
Excessive fear. See Anxiety; Fear;
Phobias

Exposure and response prevention, 73–115
classification and treatment, 100–101
considerations in, 115–119
differential effects of, 92–100
exposure processes, 101–111
outcome studies in, 73–83
success/failure with, 111–115
variants of, 83–92
See also Response prevention

Exposure procedures, 61–66
blocking procedures compared, 70–71
duration of, 86–87
gradual versus rapid mode, 87–88
imaginal versus in vivo, 83–85
processes during, 101–111
prognosis, 72–73
therapeutic relationship and, 89–90

Fantasy, 172

Fear
avoidance behavior and, 15
classification and, 57, 58
obsessive-compulsive disorders and, 10

Fear (cont.)
See also Anxiety; Phobias
Fear/avoidance model, 51–54
Fertility rates, 6
Flooding, 38, 39, 40, 61, 63, 64,
239–240
exposure and response prevention, 88, 93
Fluoxetine hydrochloride, 234–235
Focalization, 147–148, 158
Functional formulations, 222–226

Gender, 6. See also Sex differ­ences; Women

Genetics, 12–13, 157
anxiety disorders and, 226
regression and, 133
studies in, 229

Gilles de la Tourette syndrome, 168, 175, 176, 179

Habituation, 241–242
between sessions, 105–108
depression and, 114–115
prognosis and, 117–118, 119
treatment outcome and, 108–111
within sessions, 101–105

Haloperidol, 176, 179, 188

Heart rate
habituation, 101, 104, 105,
106–107
obsession and, 53

History taking, 143–144

Horrific obsessions, 70
Huntington’s chorea, 175, 176

Hypnosis, 71, 155

Imaginal desensitization, 62. See also Desensitization

Imaginal exposure
duration of, 87
in vivo exposure versus, 83–85
Imipramine, 182, 183, 189
Implosion, 40
  exposure and response prevention, 83, 87
  exposure procedures, 63, 64
  treatment, 39
Indecisiveness, 220-221
Induced anxiety, 63. See also Anxiety
Inhibition, 65
Intrusive thoughts, 25-27
  assessment and, 171-172
  classification and, 57, 58
  fear/avoidance model, 52
  See also Cognition
In vivo exposure
  duration of, 87
  imaginal exposure versus, 83-85
Isolation, 6, 134-135, 138
L-dopa, 176, 177
Learning processes, 11-12
Learning theory, 15
Leucotomy, 34, 197
  bimedial, 199-200
  limbic, 201-202
  See also Psychosurgery
Leyton Obsessive Inventory, 173-174
Limbic leucotomy, 201-202
  See also Psychosurgery
Lithium, 194, 197
L-tryptophan, 194
Magical thinking, 134
Marriage age, 6
Maudsley Obsessive Compulsive Inventory, 173, 174
Memory, 55
Methotrimeprazine, 179
Modeling, 40
  exposure and response prevention therapy, 83, 80-89
Modeling (cont.)
  prognosis, 39
  treatment, 38
Monoamine oxidase inhibitors (MAOIs), 192-193
Mood, 9, 28-29
Morbid preoccupations. See Preoccupations
Motivation, 142-143
Neuroleptics, 178-179
Neurosis
  exposure and response prevention therapy, 84
  obsessive-compulsive disorders and, 5-6
  See also Anxiety; Depression; Psychiatric disorders
Normality, 27-28
Obsessional slowness, 218
  classification, 56-57
  diagnosis, 169, 221
  treatment, 41
Obsessions
  anxiety and, 53
  behavioral treatment, 60-61
  compulsions and, 3
  conditions in, 4
  content of, 2
  defined, 2, 50-51
  delusions contrasted, 8
  depression and, 9-10
  exposure procedures and, 62-63
  horrific obsessions, 70
  nature of, 24-29
  preoccupations contrasted, 8
  thought stopping procedures and, 68
  See also Compulsions; Obsessive-compulsive disorders
Obsessive-compulsive disorders (OCD)
Obsessive-compulsive disorders (cont.)
anxiety disorders and, 226–232
(See also Anxiety)
assessment of, 170–175, 243–244
(See also Assessment)
behavioral models of, 51–56
behavioral treatment of, 60–73
biochemistry of, 175–178
classificaiton of, 56–60
course of disorder, 5–7
defined, 1–2, 49–51
depression and, 169–170, 232–235
(See also Depression)
diagnosis of, 3–4, 168–170
(See also Diagnosis)
effects of, 4, 5
exposure and response prevention therapy for, 73–115
functional diversity, 216–128
functional formulations, 222–226
genesis of, 10–13
incidence of, 4
intrusive unwanted thoughts, 27
(See also Intrusive thoughts)
persistence of, 15–19
pharmacotherapy for, 167–203
phenomenological variance, 214–216
phobias contrasted, 52
(See also Phobias)
prognosis for, 6, 7, 9
(See also Prognosis)
psychodynamic explanations of, 133–135
psychological treatment for, 155–165
relation to other disorders, 7–10
short-term anxiety-provoking psychotherapy for, 131–153
treatment of, 29–42
(See also Treatment)
Pharmacotherapy (cont.)
exposure and response prevention therapy, 74-75, 113
exposure procedures and, 61, 63
future research, 237, 239
psychosurgery, 195-202
treatment, 30-32, 178-195
Phenmetrazine, 175
Phobias
anxiety and, 227-228
assessment and, 172-173
cleaning compulsions and, 14
exposure and response prevention therapy, 83, 117
exposure duration and, 86-87
habituation and, 109-110
obsessive-compulsive disorders and, 10, 52
treatment of, 38, 39
Predictor variables, 240-243
Preoccupations, 8
Primary obsessional slowness. See Obsessional slowness
Prognosis
apotrepic therapy, 73, 74, 75
aversion-relief paradigm, 66, 67
behavioral therapy, 38, 39-40, 72
blocking procedures, 67, 68
depression and, 9
exposure and response prevention therapy, 77, 78-79, 80-82, 108-115
exposure procedures, 61-62, 63, 64-65
improvement in, 238
onset mode, 11, 135
paradoxical intention, 64
pessimism in, 167
predictor variables, 240-243
psychosurgery, 36-37
psychotherapy, 151-153
Prognosis (cont.)
thought stopping, 69
treatment and, 29-30
See also Assessment; Diagnosis
Psychiatric disorders, 13, 226-235.
See also Anxiety; Depression; Neurosis
Psychoanalysis, 219-220. See also Psychotherapy; Short-term anxiety-provoking psychotherapy (STAPP)
Psychosis, 7, 175, 176
Psychosurgery, 32-37, 195-202
Psychotherapy
behavior therapy contrasted, 157-160, 163-164
exposure procedures with, 61
ineffectiveness of, 60
obsessive-compulsive disorders and, 155, 157
process of, 161-163
thought stopping and, 69
treatment, 32
Pure obsessions, 41-42
See also Obsessions
Reaction formation, 134, 138
Reactivity, 108-111
Regression, 133-134, 138
Reinforcement
behavioral treatment, 60
fear/avoidance model, 51-52
Relapse
exposure and response prevention therapy, 75-76
psychosurgery and, 197-198
See also Prognosis
Relaxation techniques, 71
apotrepic therapy compared, 74
exposure procedures and, 62, 63, 110
thought stopping and, 68-69
Remission. See Spontaneous remission
Repeater compulsions, 56
Resistance
diagnosis and, 168, 218–219
intrusive thoughts and, 171–172
measurement of, 173, 174
normal obsessions and, 28
obsessive-compulsive disorders and, 4, 5, 8, 14
Response prevention, 40–41
differential effects, 92–100
pharmacotherapy with, 189
variants of, 90–92
See also Exposure and response prevention
Rituals
anxiety and, 217
assessment and, 172
measurement of, 173, 174
phobias and, 52
severity measurement, 173
See also Compulsions
Ruminators, 99–100
Satiation, 61, 64–65
Schizophrenia, 175
compulsions contrasted, 8
diagnosis and, 168
obsessive-compulsive disorders and, 7
psychosurgery and, 33, 35
Self-esteem, 161
Senile dyskinesia, 175
Serotonin, 178, 194
Sex differences
checking compulsions, 14
cleaning compulsions, 14
course of disorder and, 6
Short-term anxiety-provoking psychotherapy (STAPP), 131–153
clinical case of, 131–133
Short-term anxiety-provoking psychotherapy (STAPP) (cont.)
description of, 136–145
diagnosis and, 236
techniques of, 145–153
Skin conductance, 53, 117–118
Slowness. See Obsessional slowness
Social isolation. See Isolation
Social learning theory, 39
Spontaneous decay, 21–23, 24
Spontaneous remission
assessment and, 170–171
rates of, 6, 7, 30
therapy and, 29
Stereotactic tractotomy, 196–197, 199
Suicide, 6
Surgery. See Psychosurgery
Symptomatology, 112
Symptom substitution, 158
Systematic desensitization, 61, 62, 70
Tardive dyskinesia, 176
Therapeutic modeling. See Modeling
Therapeutic relationship
psychotherapy and, 145–147
treatment and, 155–156
Therapists
exposure and response prevention, 89–90
psychotherapy and, 137
Therapy. See Treatment
Thought stopping, 64–65, 68–69
Tourette’s syndrome. See Gilles de la Tourette syndrome
Transference, 141, 146, 147
Transference neurosis, 146, 148
Treatment, 29–42
assessment and, 170, 243–244
behavioral therapy, 37–41
INDEX

Treatment (cont.)
classification and, 57
defined, 159
effectiveness of, 167
future research, 235-239
goals of, 158, 162-163
pharmacotherapy, 30-32, 167-203
prognosis and, 29-30
psychosurgery, 32-37, 195-202
psychotherapy, 32 (See also Psychotherapy; Short-term anxiety-provoking psychotherapy)
spontaneous decay and, 24

Tricyclic antidepressants, 181-183, 192, 233
Trifluoperazine, 179
Twin studies, 12-13. See also Genetics
Undoing, 135, 138
Urges, 3

Washing compulsions
classification, 56
exposure and response prevention therapy, 77
Women, 11. See also Sex differences
Zimeldine, 192